Castle Creek Pharma has assembled a robust and well diversified portfolio of innovative and high potential late stage drug candidates in development for the treatment of a number of important diseases. Castle Creek Pharma’s products are advancing rapidly through development and have the potential to enter the market within 2-3 years.

Epidermolysis Bullosa Simplex

  • Epidermolysis bullosa simplex (EBS) is the most common form of epidermolysis bullosa, a rare dermatologic condition where patients (many of them children) have a genetic defect that compromises the structural integrity of their skin, making it particularly fragile and prone to blistering throughout their bodies. The disease can be severely debilitating and there are no treatment options currently available.
  • CCP-020 (diacerein topical ointment) is a new drug in development for the treatment of EBS. It is believed to block an important inflammatory signaling pathway in EBS.

Recessive Dystrophic Epidermolysis Bullosa

  • Recessive dystrophic epidermolysis bullosa (RDEB) is a life-threatening genetic disorder that is diagnosed in infancy and causes severe blistering and areas of missing skin, which is a response to any kind of friction, including normal daily occurrences like rubbing or scratching.
  • A pivotal Phase 3 clinical trial evaluating a gene therapy candidate, FCX-007, has been initiated for the treatment of RDEB.

Localized Scleroderma

  • Localized scleroderma is a chronic autoimmune disorder characterized by excessive collagen deposition resulting in thickening of the dermis and underlying tissue that can result in significant morbidity, including pain, restricted motion, disfigurement and developmental issues.
  • A Phase 1/2 clinical trial evaluating FCX-013 for the treatment of moderate to severe localized scleroderma is currently enrolling.